Association between Expression of Her-2/neu Gene and Estrogen Receptors, Progesterone Receptors and p53 Gene among Female with Primary Breast Cancer

Document Type : Original Article


1 Lecturer, Ramsar Faculty of Nursing & Midwifery, Babol University of Medical Sciences, Ramsar, Iran.

2 Assistant Professor of Internal Medicine, Tonekabon Islamic Azad University, Ramsar, Iran.

3 Radiologist, Imam Sajjad Hospital, Ramsar, Iran.

4 Pathologist, Rasht, Iran


Introduction:Considering the importance of breast cancer, identifying the factors that may either directly or indirectly determine the final prognosis of afflicted patients is helpful in clinical decision making, clinical approach and treatment of disease. Determination, expression and evaluation of estrogen receptors (ER), progesterone receptors (PR), human epidermal growth factor receptor (Her-2/neu) and p53 gene are somehow effective in prognoses and treatment of the disease. The purpose of this study is to recognize if any relationship exists between Her-2/neu gene amplification and estrogen receptor (ER), progesterone receptor (PR) and p53 gene among female with breast cancer.
Methods: This descriptive cross-sectional study is performed on 67 women with primary breast cancer whom were hospitalized at oncology ward in Emam Sajjad Hospital (Ramsar, Iran, 2001-2005). Data were gathered from participants medical records, based on Her2/neu gene amplification, estrogen receptor (ER), progesterone receptor (PR) and p53 gene. Samples were evaluated by semi-quantitative immunohistochemistry method using Her-2/neu gene amplification kit, along with ER, PR and p53 gene amplification kits. Data were analyzed by descriptive and analytic statistic tests.
Results: It was revealed that 50.7% of studied cases had positive ER, whereas 43.3% were PR positive, 31.3% were p53-positive and 31.3% had positive Her-2/neu. Her-2/neu gene was amplified in 14.2% of ER/PR positive cases andin 66.7% of ER/PR negative subjects. Uusing Chi-square test it was revealed that there is statistically significant correlations between Her-2/neu expression and positive ER (p<0.030), positive PR (p<0.014), simultaneous expression of ER and PR (p<0.001), negative PR and ER expression(p<0.004) and positive family history for cancer (p<0.003), respectively. In addition, no correlation was found between Her-2/neu expression and p53 gene, age, menopause and marital age of patients.
Conclusion: Regarding the significant correlation between Her-2/neu amplification and state of estrogen/progesterone receptors, and more significant correlation between Her-2/neu amplification and estrogen/progesterone receptor-negative tumors we can apply exclusive treatment modalities.


1. Davati A, Tavakoli A, Jalali Nadoushan MR. MExpression of Bcl-2 Gene in Primary Breast Cancer and its
Correlation with Some Prognostic Factors. Journal of Mazandaran University of Medical Sciences
2007:17(58):30-6. [Article in Farsi]
2. Iranian Ministry of Health, Deputy for Health Directory, CDC, Cancer Office. National cancer registry
report 2006-2007. 3rd ed. Tehran: Center for Disease Control Publication; 2007. p. 27-9. [Text in Farsi]
3. Siziopikou KP, Ariga R, Proussaloglou KE, Gattuso P, Cobleigh M. The challenging estrogen receptornegative/
progesterone receptor-negative/HER-2-negative patient: a promising candidate for epidermal
growth factor receptor-targeted therapy? Breast J 2006;12(4):360-2.
4. Hashemi E, Montazeri A, Akbari ME, Najafi M, Haghighat Sh, Kaviani A. Role of Tumor Markers in Breast
Cancer Recurrence. Guilan University of Medical Sciences Journal 2006;15(57):23-28. [Article in Farsi]
5. Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K, Gerber B. Expression of Her2/neu, steroid
receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal
carcinoma In Situ (DCIS) Versus invasive breast cancer alone. Anticancer Res 2005;25(3A):1719-23.
6. Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P. Correlation of her-2/neu gene amplification
with other prognostic and predictive factors in female breast carcinoma. Breast J 2005;11(4):278-80.
7. Pinto AE, André S, Pereira T, Nóbrega S, Soares J. C-erbB-2 oncoprotein overexpression identifies a
subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis. Ann Oncol 2001
8. Nyagol J, Nyong'o A, Byakika B, Muchiri L, Cocco M, de Santi MM, et al Routine assessment of hormonal
receptor and her-2/neu status underscores the need for more therapeutic targets in Kenyan women with
breast cancer. Anal Quant Cytol Histol 2006;28(2):97-103.
9. Xu R, Feiner H, Li P, Yee H, Inghirami G, Delgado Y, et al. Differential amplification and overexpression
of HER-2/neu, p53, MIB1, and estrogen receptor/progesterone receptor among medullary carcinoma,
atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast. Arch Pathol Lab Med
10. Lal P, Salazar PA, Ladanyi M, Chen B. Impact of polysomy 17 on HER-2/neu immunohistochemistry in
breast carcinomas without HER-2/neu gene amplification. J Mol Diagn 2003;5(3):155-9.
11. Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, et al. Quantitative association
between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
J Natl Cancer Inst 2003;95(2):142-53.
12. Montgomery KG, Gertig DM, Baxter SW, Milne RL, Dite GS, McCredie MR, et al. The HER2 I655V
polymorphism and risk of breast cancer in women < age 40 years. Cancer Epidemiol Biomarkers Prev
13. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, et al. erbB-2 and response to doxorubicin in
patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst
14. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by
immunohistochemical analysis. Mod Pathol 1998; 11(2):155-68.
15. Naghshvar F, Torabizadeh Zh, Emadian O, Zare A, Ghahremani M. Status of estrogene, progesterone
receptors and HER-2/neu expression in invasive breast cancer. Journal of Gorgan University of Medical
Sciences 2007;8(4):64-7. [Article in Farsi].
16. Guarneri V, Giovannelli S, Ficarra G, Bettelli S, Maiorana A, Piacentini F, et al. Comparison of HER-2 and
hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on
patient management. Oncologist 2008;13(8):838-44.
17. Lüftner D, Lüke C, Possinger K. Serum Her-2 in the management of breast cancer patient. Clin Biochem
18. Fakheri T, Najafi B, Fadakar Soogheh GH. Correlation Of P53 Protein Expression with Clinicopathologic
Parameters and Hormonal Receptor Status in Breast Cancer Patients. Guilan University of Medical
Sciences Journal 2006;15(58):1-6. [Article in Farsi]
19. Ferrero-Poüs M, Hacène K, Bouchet C, Le Doussal V, Tubiana-Hulin M, Spyratos F. Relationship between
c-erbB-2 and other tumor characteristics in breast cancer prognosis. Clin Cancer Res 2000;6(12): 4745-54.
20. Quddus RM, Sung JC, Zhang C, Pasqueriello T, Eklund M, Steinhoff MM. HER-2/neu expression
in locally advanced breast carcinomas: pre-and post-neoadjuvant chemotherapy. Breast Cancer